Molecular Insight Pharmaceuticals, Inc.
- UEI
- V168LQHKAAH7
- CAGE
- Not on record
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Entity structure
- Other
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| P186050 dota-(TYR3)-octreotide acetate salt | Office of the Chief Operating Officer | $0 | |
| Development of a kit based pet molecular imaging agent: edotreotide GA 68 for so | National Institutes of Health | $262,993 | |
| A molecular targeting agent for systemic radiotherapy of metastatic prostate canc | National Institutes of Health | $243,101 | |
| Targeting tumor hypoxia with radiohalogenated inhibitors of carbonic anhydrase IX | National Institutes of Health | $299,680 | |
| Development of a molecular targeting agent for psma to diagnose metastatic prosta | National Institutes of Health | $1,624,726 |
Quick answers
What is Molecular Insight Pharmaceuticals, Inc.'s UEI?
Molecular Insight Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is V168LQHKAAH7.
Is Molecular Insight Pharmaceuticals, Inc. registered in SAM.gov?
Molecular Insight Pharmaceuticals, Inc.'s SAM.gov registration expired on February 11, 2011.
What is Molecular Insight Pharmaceuticals, Inc.'s most recent federal award?
Molecular Insight Pharmaceuticals, Inc.'s most recent federal contract award is P186050 dota-(TYR3)-octreotide acetate salt (HHSN269201100120P), from Office of the Chief Operating Officer, on February 11, 2011.
On GovTribe
See Molecular Insight Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors